Russell Investments Group Ltd. grew its position in Definium Therapeutics, Inc. (NASDAQ:DFTX – Free Report) by 116.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 331,702 shares of the company’s stock after purchasing an additional 178,225 shares during the period. Russell Investments Group Ltd.’s holdings in Definium Therapeutics were worth $12,647,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in DFTX. Lisanti Capital Growth LLC acquired a new stake in shares of Definium Therapeutics in the third quarter valued at approximately $2,647,000. Pictet Asset Management Holding SA raised its holdings in shares of Definium Therapeutics by 32.7% during the third quarter. Pictet Asset Management Holding SA now owns 18,674 shares of the company’s stock valued at $711,000 after buying an additional 4,597 shares during the last quarter. AlphaCentric Advisors LLC acquired a new position in shares of Definium Therapeutics during the third quarter worth approximately $366,000. Alps Advisors Inc. boosted its position in shares of Definium Therapeutics by 61.3% during the third quarter. Alps Advisors Inc. now owns 178,006 shares of the company’s stock worth $6,775,000 after buying an additional 67,618 shares during the period. Finally, Commonwealth Equity Services LLC boosted its position in shares of Definium Therapeutics by 4.0% during the third quarter. Commonwealth Equity Services LLC now owns 9,832 shares of the company’s stock worth $374,000 after buying an additional 382 shares during the period. Institutional investors and hedge funds own 27.91% of the company’s stock.
Definium Therapeutics Stock Down 3.9%
Definium Therapeutics stock opened at $28.34 on Friday. Definium Therapeutics, Inc. has a 52 week low of $10.46 and a 52 week high of $49.70. The stock has a market cap of $3.88 billion, a price-to-earnings ratio of -9.11 and a beta of 2.23. The company’s 50-day moving average price is $35.18 and its two-hundred day moving average price is $30.68. The company has a current ratio of 15.53, a quick ratio of 15.53 and a debt-to-equity ratio of 0.04.
Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.09. On average, analysts expect that Definium Therapeutics, Inc. will post -2.94 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities analysts recently issued reports on the company. UBS Group reissued a “buy” rating and issued a $70.00 price objective on shares of Definium Therapeutics in a report on Tuesday, September 15th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 target price on shares of Definium Therapeutics in a research note on Monday, September 14th. JonesTrading boosted their price target on Definium Therapeutics from $74.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. Robert W. Baird boosted their price target on Definium Therapeutics from $75.00 to $79.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 15th. Finally, Royal Bank Of Canada increased their price target on Definium Therapeutics from $66.00 to $70.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 10th. Nineteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $66.29.
Check Out Our Latest Analysis on Definium Therapeutics
Insider Activity at Definium Therapeutics
In other Definium Therapeutics news, insider Mark Sullivan sold 14,051 shares of the stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $513,845.07. Following the completion of the transaction, the insider directly owned 494,228 shares of the company’s stock, valued at approximately $18,073,917.96. This trade represents a 2.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert Barrow sold 31,550 shares of the stock in a transaction on Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $1,153,783.50. Following the transaction, the chief executive officer directly owned 2,213,090 shares of the company’s stock, valued at approximately $80,932,701.30. The trade was a 1.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 71,098 shares of company stock worth $2,626,115 over the last ninety days. Insiders own 2.40% of the company’s stock.
Definium Therapeutics Company Profile
Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.
Featured Articles
- Five stocks we like better than Definium Therapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding DFTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Definium Therapeutics, Inc. (NASDAQ:DFTX – Free Report).
Receive News & Ratings for Definium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
